Influence of cepharanthin on the intracellular accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo

Koji Nishikawa, Jun-Ichi Asaumi, Shoji Kawasaki, Masahiro Kuroda, Yoshihiro Takeda, Yoshio Hiraki

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Cepharanthin enhances the cytotoxicity of adriamycin by inhibiting its efflux incorporated into cancer cells. Therefore, it may also enhance accumulation of adriamycin, and then enhance toxicity by adriamycin in normal cells as well as in cancer cells. In this study, we first examined influence of cepharanthin on the accumulation of adriamycin in normal liver cells or spleen cells in vitro and in vivo. Cepharanthin lowered the accumulation of adriamycin in liver cells, in both in vitro and in vivo. In spleen cells, it enhanced adriamycin accumulation slightly in vitro, but did not affect that in vivo. Further, cepharanthin lowered the amount of adriamycin in plasma. This suggests that decreased levels of adriamycin in plasma may be one of factors in the decrease of adriamycin accumulation in liver cells. On the other hand, cepharanthin enhanced the NK2280 accumulation used for an indicator of cell membrane potential for 60-100 minutes in liver cells, but did not change that in spleen cells. These suggest that the cell membrane potential may not affect the adriamycin accumulation in both cells since adriamycin accumulation increases with increasing accumulation of NK-2280. Moreover, no change in adriamycin efflux of liver cells was demonstrated by the treatment of cepharanthin. This indicates that the decrease in adriamycin accumulation in liver cells may not be due to the inhibition of adriamycin efflux. In conclusion, cepharanthin enhances adriamycin accumulation in cancer cells, but lowers it accumulation in normal liver cells, and does not affect that in spleen cells. Therefore, cepharanthin may be useful in cancer chemotherapy.

Original languageEnglish
Pages (from-to)3617-3621
Number of pages5
JournalAnticancer Research
Volume17
Issue number5 A
Publication statusPublished - Sep 1997

Fingerprint

Doxorubicin
Spleen
Liver
cepharanthine
In Vitro Techniques
Membrane Potentials
Neoplasms
Cell Membrane

Keywords

  • Adriamycin
  • Cepharanthin
  • Liver cells
  • Spleen cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Influence of cepharanthin on the intracellular accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo. / Nishikawa, Koji; Asaumi, Jun-Ichi; Kawasaki, Shoji; Kuroda, Masahiro; Takeda, Yoshihiro; Hiraki, Yoshio.

In: Anticancer Research, Vol. 17, No. 5 A, 09.1997, p. 3617-3621.

Research output: Contribution to journalArticle

@article{07ddeb57637e41b282955c28ae5fa198,
title = "Influence of cepharanthin on the intracellular accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo",
abstract = "Cepharanthin enhances the cytotoxicity of adriamycin by inhibiting its efflux incorporated into cancer cells. Therefore, it may also enhance accumulation of adriamycin, and then enhance toxicity by adriamycin in normal cells as well as in cancer cells. In this study, we first examined influence of cepharanthin on the accumulation of adriamycin in normal liver cells or spleen cells in vitro and in vivo. Cepharanthin lowered the accumulation of adriamycin in liver cells, in both in vitro and in vivo. In spleen cells, it enhanced adriamycin accumulation slightly in vitro, but did not affect that in vivo. Further, cepharanthin lowered the amount of adriamycin in plasma. This suggests that decreased levels of adriamycin in plasma may be one of factors in the decrease of adriamycin accumulation in liver cells. On the other hand, cepharanthin enhanced the NK2280 accumulation used for an indicator of cell membrane potential for 60-100 minutes in liver cells, but did not change that in spleen cells. These suggest that the cell membrane potential may not affect the adriamycin accumulation in both cells since adriamycin accumulation increases with increasing accumulation of NK-2280. Moreover, no change in adriamycin efflux of liver cells was demonstrated by the treatment of cepharanthin. This indicates that the decrease in adriamycin accumulation in liver cells may not be due to the inhibition of adriamycin efflux. In conclusion, cepharanthin enhances adriamycin accumulation in cancer cells, but lowers it accumulation in normal liver cells, and does not affect that in spleen cells. Therefore, cepharanthin may be useful in cancer chemotherapy.",
keywords = "Adriamycin, Cepharanthin, Liver cells, Spleen cells",
author = "Koji Nishikawa and Jun-Ichi Asaumi and Shoji Kawasaki and Masahiro Kuroda and Yoshihiro Takeda and Yoshio Hiraki",
year = "1997",
month = "9",
language = "English",
volume = "17",
pages = "3617--3621",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 A",

}

TY - JOUR

T1 - Influence of cepharanthin on the intracellular accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo

AU - Nishikawa, Koji

AU - Asaumi, Jun-Ichi

AU - Kawasaki, Shoji

AU - Kuroda, Masahiro

AU - Takeda, Yoshihiro

AU - Hiraki, Yoshio

PY - 1997/9

Y1 - 1997/9

N2 - Cepharanthin enhances the cytotoxicity of adriamycin by inhibiting its efflux incorporated into cancer cells. Therefore, it may also enhance accumulation of adriamycin, and then enhance toxicity by adriamycin in normal cells as well as in cancer cells. In this study, we first examined influence of cepharanthin on the accumulation of adriamycin in normal liver cells or spleen cells in vitro and in vivo. Cepharanthin lowered the accumulation of adriamycin in liver cells, in both in vitro and in vivo. In spleen cells, it enhanced adriamycin accumulation slightly in vitro, but did not affect that in vivo. Further, cepharanthin lowered the amount of adriamycin in plasma. This suggests that decreased levels of adriamycin in plasma may be one of factors in the decrease of adriamycin accumulation in liver cells. On the other hand, cepharanthin enhanced the NK2280 accumulation used for an indicator of cell membrane potential for 60-100 minutes in liver cells, but did not change that in spleen cells. These suggest that the cell membrane potential may not affect the adriamycin accumulation in both cells since adriamycin accumulation increases with increasing accumulation of NK-2280. Moreover, no change in adriamycin efflux of liver cells was demonstrated by the treatment of cepharanthin. This indicates that the decrease in adriamycin accumulation in liver cells may not be due to the inhibition of adriamycin efflux. In conclusion, cepharanthin enhances adriamycin accumulation in cancer cells, but lowers it accumulation in normal liver cells, and does not affect that in spleen cells. Therefore, cepharanthin may be useful in cancer chemotherapy.

AB - Cepharanthin enhances the cytotoxicity of adriamycin by inhibiting its efflux incorporated into cancer cells. Therefore, it may also enhance accumulation of adriamycin, and then enhance toxicity by adriamycin in normal cells as well as in cancer cells. In this study, we first examined influence of cepharanthin on the accumulation of adriamycin in normal liver cells or spleen cells in vitro and in vivo. Cepharanthin lowered the accumulation of adriamycin in liver cells, in both in vitro and in vivo. In spleen cells, it enhanced adriamycin accumulation slightly in vitro, but did not affect that in vivo. Further, cepharanthin lowered the amount of adriamycin in plasma. This suggests that decreased levels of adriamycin in plasma may be one of factors in the decrease of adriamycin accumulation in liver cells. On the other hand, cepharanthin enhanced the NK2280 accumulation used for an indicator of cell membrane potential for 60-100 minutes in liver cells, but did not change that in spleen cells. These suggest that the cell membrane potential may not affect the adriamycin accumulation in both cells since adriamycin accumulation increases with increasing accumulation of NK-2280. Moreover, no change in adriamycin efflux of liver cells was demonstrated by the treatment of cepharanthin. This indicates that the decrease in adriamycin accumulation in liver cells may not be due to the inhibition of adriamycin efflux. In conclusion, cepharanthin enhances adriamycin accumulation in cancer cells, but lowers it accumulation in normal liver cells, and does not affect that in spleen cells. Therefore, cepharanthin may be useful in cancer chemotherapy.

KW - Adriamycin

KW - Cepharanthin

KW - Liver cells

KW - Spleen cells

UR - http://www.scopus.com/inward/record.url?scp=0030731518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030731518&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 3617

EP - 3621

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 A

ER -